Mike Doustdar, CEO of Novo Nordisk, launches a company rebrand and corporate culture as industry rivals and patent expiries ...
The Ozempic maker is partnering with the AI firm to speed up drug development.
On August 31, 2026, Reuters reported on a new study finding that patients who stay on the lowest starter doses of GLP-1 ...
Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a strategic collaboration and license agreement ...
Sept 14 - Novo Nordisk is changing its day-to-day name to 'Novo', and taking a new approach to company culture as it looks to ...
Novo Nordisk stock rises after CHMP backs FREHEMGO for haemophilia A, moving the drug closer to EU approval and a planned ...
Much like GSK (formerly GlaxoSmithKline) and the once Sanofi-Aventis (now just Sanofi), Novo Nordisk is slimming down its ...
Novo Nordisk A/S ( NVO) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for ...
Orbis Medicines said on Thursday it had signed a drug discovery and licensing deal with Novo Nordisk worth up to $1.4 billion ...
3don MSN
Novo Nordisk is changing its name and its culture to try to compete in the GLP-1 diet-drug wars
The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.
Novo Nordisk (NVO) stock is in focus after signing a $1.4B deal with Orbis Medicines to develop oral drugs for ...
Novo Nordisk is partnering with Anthropic to use artificial intelligence to accelerate the discovery and development of new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results